CRNX - Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends. Analyst Ratings This is a summary of current
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the Company's continued growth and diversification. Completion of Acquisition of Crinetic.
BlackRock Inc. purchased a new position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 9,758,938 shares of the company's stock, valued at approximately $365,179,000. BlackRock Inc. owned approximately 9.20% of
AWM Investment Company Inc. bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 85,000 shares of the company's stock, valued at approximately $3,181,000. AWM Investment Company Inc. owned approximately 0.08% of Crinetics Pharmaceuticals
Deutsche Bank AG purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 283,727 shares of the company's stock, valued at approximately $10,617,000. Deutsche Bank AG owned about 0.27% of
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 17, 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propos
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this considerati.
Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Towa Pharmaceutical (OTCMKTS:TWAPF - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Profitability This table compares Crinetics Pharmaceuticals and Towa
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to a loss of $1.23 per share a year ago.
Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--ACA, CRNX, LEG, and LPSN PR Newswire
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
MILWAUKEE, July 21, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex.
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating